Crizotinib may also be a suitable drug to increase the sensitivity of DLBCL cells to R-CHOP treatment, so in addition to the R-CHOP regimen, crizotinib/EMT pathway will likely be a new idea for the treatment of non-Hodgkin lymphoma. The gene discussed is DDIT3; the disease is non-Hodgkin lymphoma.